Work

Real-world drug survival of tildrakizumab for plaque psoriasis: a 3-year international multicentre retrospective study

Year: 2025
Type: article
Study design: Observational Study
Abstract: Tildrakizumab is a monoclonal antibody targeting interleukin-23 that has gained regulatory approval for moderate-to-severe plaque psoriasis in several jurisdictions. While phase III clinical trials have evaluated its short-term efficacy and safety, real-world evidence regarding its long-term retention is limited. We report real-world drug survival of tildrakizumab in the routine clinical setting.
Language: English
Subfield: Immunology
Open Access status: green
OpenAlex ID: W4412725534
FWCI: 1.102
Cites: 5
Cited by: 4
Related to: 9